Skip to Main Content

288

Views

1

CrossRef citations to date

0

Altmetric

Original Articles

A randomized phase II study comparing consolidation with a single dose of ⁹⁰Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Armando López-Guillermoa Hematopathology Department, Hospital Clinic de Barcelona, Barcelona, SpainCorrespondence[email protected]

https://orcid.org/0000-0002-8588-8381 View further author information

,

Miguel Ángel Canalesb Hematology Department, Hospital La Paz, Madrid, SpainView further author information

,

Ivan Dlouhya Hematopathology Department, Hospital Clinic de Barcelona, Barcelona, SpainView further author information

,

Santiago Mercadalc Catalan Institute of Oncology, Hospital Bellvitge, Barcelona, SpainView further author information

,

Javier Brionesd Hospital de la Santa Creu y Sant Pau, Barcelona, SpainView further author information

,

Alejandro Martín García-Sanchoe Hospital Clinico, Salamanca, SpainView further author information

,

Juan Manuel Sanchof Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, SpainView further author information

,

José María Moraledag Hematology Department, Hospital V. Arraixaca, Murcia, Spain

https://orcid.org/0000-0001-9080-1466 View further author information

,

María José Terolh Department of Haematology and Medical Oncology, Hospital Clinico, Valencia, SpainView further author information

,

Antonio Salari Hematology Department, Hospital del Mar, Barcelona, SpainView further author information

,

Luis Palomeraj Hematology Department, Hospital Clínico Lozano Blesa, Zaragoza, SpainView further author information

,

Santiago Gardellak Catalan Institute of Oncology, Hospital Josep Trueta, Girona, SpainView further author information

,

Isidro Jarquel Hematology Department, Hospital La Fe, CIBERONC – Instituto Carlos III, Valencia, SpainView further author information

,

Secundino Ferrerm Hematology Department, Hospital Dr. Peset, Valencia, SpainView further author information

,

Joan Bargayn Hospital Son Llatzer, Mallorca, SpainView further author information

,

Andrés Lópezo Hematology Department, Hospital Vall d’Hebron, Barcelona, SpainView further author information

,

Carlos Panizop Hematology Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information

,

Anna Muntañolaq Hematology Department, Hospital Universitari Mutua de Terrassa, Terrassa, SpainView further author information

,

Carlos Montalbánr Internal Medicine, Hospital Ramón y Cajal, Madrid, SpainView further author information

,

Eulogio Condes Department of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, SpainView further author information

,

Miguel T. Hernándezt Hematology Department, Hospital Universitario de Canarias, Tenerife, SpainView further author information

,

Alfons Soleru Hematology Department, Hospital Parc Taulí, Sabadell, SpainView further author information

,

José A. García Marcov Hospital Puerta de Hierro, Madrid, SpainView further author information

,

Guillermo Debenw Hematology Department, Hospital Juan Canalejo, La Coruña, SpainView further author information

,

Julián Marínx Hematology Department, Hospital Nuestra Señora de Aránzazu, San Sebastián, SpainView further author information

,

José Francisco Tomásy Hematology Department, MD Anderson Cancer Center, Madrid, SpainView further author information

& for the PETHEMA/GELTAMO/GELCAB Spanish Intergroup show all